I am a medicinal chemist that either directed or helped drive the discovery of multiple NCE's that led to the filing of IND applications and Clinical Trials. I have a proven track record of success in the PI3K and mTOR arenas, as well as expertise with the inhibition of other kinases and targets, including cKit, Chk1, Jnk, and Hsp90. I have extensive experience with the modulation of nuclear hormone receptors including RORgamma, FXR and LXR. I have approximately forty total patents and applications twenty U.S. Patents.ACCOMPLISHMENTS: CLINICAL TRIALS AND INDsI either led, or helped drive, six projects to IND filings. Five of the new chemical entities entered human clinical trials, mostly in oncology. Eleven Phase I and Phase II clinical trials were run on voxtalisib.• CC-401: JNK Inhibitor (IND, Phase I, Signal / Celgene)• XL844: Chk1 Inhibitor (IND, Phase I, Partnered with GSK)• XL335: FXR Agonist (IND, Phase I, Partnered with Wyeth as WAY-362450)• XL765: PI3K/ mTOR Inhibitor (IND, Phase II, Voxtalisib, Partnered with Sanofi)• XL888: HSP90 Inhibitor (IND, Phase I)• XL388: mTOR Inhibitor (IND Filed)
Visionary Pharmaceuticals
-
ConsultantVisionary Pharmaceuticals Apr 2020 - PresentSan Diego, California, United States
-
Vice President Of ChemistryTrisaq, Inc. Oct 2019 - Apr 2020Cambridge, MaI led a program to make allosteric agonists of human dynamin to treat Chronic Kidney Disease (CKD). Dynamin modulates actin and the cytoskeleton involved in maintaining foot process integrity in podocytes. Loss of foot process integrity in podocytes gives rise to proteinuria and CKD.
-
Vice President Of Medicinal ChemistryVisionary Pharmaceuticals Apr 2018 - Sep 2019San Diego, CaI directed all medicinal chemistry efforts on the antagonism of RORgamma, an important modulator of IL-17.
-
Senior Director Of Medicinal ChemistryVisionary Pharmaceuticals 2013 - Mar 2018San Diego, CaI directed the medicinal chemistry efforts on a RORgamma modulator program. RORgamma is a nuclear hormone receptor that is implicated in a number of inflammatory diseases, alcoholic liver disease, and NASH. I directed all of the chemistry, and many supporting biological studies, through contract research organizations.
-
Pharmaceutical ConsultantConsultant 2012 - 2013I provided drug discovery consulting services to the pharmaceutical industry.
-
Director Of Medicinal ChemistryExelixis 2006 - 2011South San Francisco, CaI directed major research and development projects, from conception to clinical trial and/or IND filing. Orchestrated key cross-functional partnerships to support project success. Led drug discovery initiatives and delivered final products for transfer to process chemistry.Highlights• Drove all aspects of medicinal chemistry efforts for developmental of XL765 PI3K/mTOR inhibitor, voxtalisib, for solid tumor cancer treatment with potential for large market. The inhibitor was in eleven Phase I and Phase II clinical trials with partner Sanofi Aventis as SAR245409. Voxtalisib was in clinical trials for eleven years.• Coordinated and co-directed medicinal chemistry efforts in development and IND filing of selective mTOR inhibitor (XL388).• Provided key support in discovery of HSP90 Inhibitor (XL888) that entered clinical trials. -
Associate Director Of Medicinal ChemistryExelixis 2002 - 2006South San Francisco, CaLed a team of medicinal chemists in a wide range of projects, focussing on metabolism and oncology targets. Moved key projects to advanced research stages. Supported efforts of additional research projects and focuses. Led larger teams of medicinal chemists (over 15) as project leader.Highlights• Directed medicinal chemistry efforts to advance Chk1 protein kinase inhibitor (XL844) to human Phase 1 clinical trials for cancer. XL844 was first small molecule Chk1 inhibitor to enter clinical trials.
-
Senior Research ScientistExelixis 2001 - 2002South San FranciscoManaged all medicinal chemistry aspects of Chk1 inhibitor project. Supervised large chemistry team as the chemistry project leader.Highlights• Drove significant improvements in the in vitro and cellular potencies of Chk1 inhibitors, resulting in filing of patent application and advancement of project to preclinical stage.
-
Senior Research ScientistSignal Pharmaceuticals / Celgene Corporation 1999 - 2001San Diego, CaSynthesized selective low nanomolar Jun kinase (JNK) inhibitors. Studied in vitro, cellular, and animal structure activity relationships, as well as pharmacokinetics of these molecules. Highlights• Synthesized and discovered CC-401, which entered Phase 1 clinical trials.
-
Research ScientistGilead Sciences Jun 1988 - Jul 1999Foster City, CaI was the sixth hire, and second Ph.D. at Gilead Sciences. Led various research projects, with special focus on synthesis and structure-activity relationships of small antiviral molecules, nucleosides, and oligonucleotides. Synthesized numerous heterocycles, nucleosides, oligonucleotides, and antiviral compounds.
Chris Buhr Skills
Chris Buhr Education Details
-
Organic Chemistry -
Organic Chemistry -
Organic Chemistry
Frequently Asked Questions about Chris Buhr
What company does Chris Buhr work for?
Chris Buhr works for Visionary Pharmaceuticals
What is Chris Buhr's role at the current company?
Chris Buhr's current role is Consultant.
What schools did Chris Buhr attend?
Chris Buhr attended University Of California, Los Angeles, University Of Illinois At Urbana-Champaign, University Of Pittsburgh.
What skills is Chris Buhr known for?
Chris Buhr has skills like Synthetic Organic Chemistry, Medicinal Chemistry, Drug Discovery, Pharmaceutical Industry, Oncology, Inflammation.
Not the Chris Buhr you were looking for?
-
Chris Buhr
United States -
2thomsonreuters.com, tr.com2 +160834XXXXX
-
1injurydynamics.com -
2fcsamerica.com, fcsamerica.com2 +140234XXXXX
Free Chrome Extension
Find emails, phones & company data instantly
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial